Fast Trial Enrollment Underscores Increasing Self-Apposing Stent Adoption At European Hospitals
February 6, 2012 — A medical technology company commercializing the world's first and only self-apposing stent to treat acute myocardial infarction (AMI), announced today that the APPOSITION III clinical study successfully enrolled 1,000 patients suffering from a severe heart attack and that the final results of the examination 30 days after treatment will be presented during the upcoming EuroPCR international cardiology congress.
“Closing the study ahead of our projected timetable is a clear sign of the increasing adoption of our technology among cardiologists. The impressive interim clinical results reported two months ago should be confirmed by the final results and will prove that the self-apposing technology is the best solution for treating heart attack patients,” said Gonzague Issenmann, CEO and co-founder of Stentys.
The Stentys Self-Apposing Stent solves the stent-sizing dilemma that cardiologists are confronted with when treating heart attack patients with conventional stents. It fits snugly into the contour of a blood vessel, and its shape and diameter adapt to the anatomic changes of the coronary arteries during the post-AMI phase, avoiding a major complication of all other conventional stents: malapposition.
For more information: www.stentys.com
More like this
- Stentys Completes Enrollment of Self-Apposing Stent Trial
- Stentys Starts Trial for New Drug-Eluting Stent
- International Study to Look at Self-Apposing Stent in AMI Patients
- Stentys Launches New Stent-Delivery System to Facilitate Implantation in More Complex Anatomies
- First Patients Enrolled in Study of Self-Apposing Coronary Stent